Gilead Sciences Inc. announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy), highlighting its significant impact on patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1/PD-L1 inhibitors. The study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival $(PFS)$ compared to standard chemotherapy. This marks the second positive Phase 3 trial where Trodelvy has shown benefits over standard care for this patient group. The results suggest Trodelvy could become the backbone treatment and the first antibody-drug conjugate for all patients across first-line metastatic TNBC. This development addresses an urgent need for innovative treatment options in the early stages of mTNBC, where traditional chemotherapy has been the standard. Gilead is also conducting further Phase 3 studies of Trodelvy in other types of breast cancer and different tumor types.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.